The results showed that LPS treatment greatly increased the relative expressions of Il-1β, Il-6, Tnf-α, Ccl2, and Cxcl1, which were significantly reduced in APS pre-treatment group (Figure 3D). The gene discussed is IL1B; the disease is autoimmune polyendocrinopathy.